Science China Life Sciences

, Volume 62, Issue 9, pp 1253–1256 | Cite as

Modification of donor lymphocyte infusion: how to improve the outcome?

  • Yu Wang
  • Lanping Xu
  • Chenhua Yan
  • Xiaojun HuangEmail author


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.



This work was partly supported by grants from the National Key Research and Development Program of China (2017YFA0104500) from the Ministry of Science and Technology, National Natural Science Foundation of China (81770189, 81621001, 81530046), Collaborative Innovation Center of Hematology China, the Science and Technology Project of Guangdong Province of China (2016B030230003), and the Project of Health Collaborative Innovation of Guangzhou city (201704020214). We thank the principal investigators and the skilled teams.

Compliance and ethics The author(s) declare that they have no conflict of interest.


  1. Cheng, Y., Chen, Y., Yan, C., Wang, Y., Zhao, X., Chen, Y., Han, W., Xu, L., Zhang, X., Liu, K., et al. (2019). Donor-derived CD19-targeted T cell infusion eliminates B cell acute lymphoblastic leukemia minimal residual disease with no response to donor lymphocytes after allogeneic hematopoietic stem cell transplantation. Engineering 5, 150–155.CrossRefGoogle Scholar
  2. Ciurea, S.O., Schafer, J.R., Bassett, R., Denman, C.J., Cao, K., Willis, D., Rondon, G., Chen, J., Soebbing, D., Kaur, I., et al. (2017). Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. Blood 130, 1857–1868.CrossRefGoogle Scholar
  3. Fu, Q., Xu, L., Zhang, X., Wang, Y., Chang, Y., Liu, K., and Huang, X. (2018). Platelet transfusion refractoriness after T-cell-replete haploidentical transplantation is associated with inferior clinical outcomes. Sci China Life Sci 61, 569–577.CrossRefGoogle Scholar
  4. Goldsmith, S.R., Slade, M., DiPersio, J.F., Westervelt, P., Schroeder, M.A., Gao, F., and Romee, R. (2017). Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy. Bone Marrow Transplant 52, 1623–1628.CrossRefGoogle Scholar
  5. Huang, X., Guo, N., Ren, H., Zhang, Y., Gao, Z., and Lu, D. (2003). An improved anti-leukemic effect achieved with donor progenitor cell infusion for relapse patients after allogeneic bone marrow transplantation. Chin Med J (Engl) 116, 736–741.Google Scholar
  6. Huang, X.J., Liu, D.H., Liu, K.Y., Xu, L.P., Chen, H., and Han, W. (2007). Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 92, 414–417.CrossRefGoogle Scholar
  7. Kharfan-Dabaja, M.A., Labopin, M., Polge, E., Nishihori, T., Bazarbachi, A., Finke, J., Stadler, M., Ehninger, G., Lioure, B., Schaap, N., et al. (2018). Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. JAMA Oncol 4, 1245–1253.CrossRefGoogle Scholar
  8. Liu, Y., Huang, X., Fei, Q., Xu, L., Zhang, X., Liu, K., Chen, Y., Chen, H., and Wang, Y. (2019). Comparison analysis between haplo identical stem cell transplantation and matched sibling donor stem cell transplantation for high-risk acute myeloid leukemia in first complete remission. Sci China Life Sci 62, 691–697.CrossRefGoogle Scholar
  9. Qin, Y.Z., Wang, Y., Xu, L.P., Zhang, X.H., Chen, H., Han, W., Chen, Y.H., Wang, F.R., Wang, J.Z., Chen, Y., et al. (2017). The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. J Hematol Oncol 10, 44.CrossRefGoogle Scholar
  10. Tsirigotis, P., Byrne, M., Schmid, C., Baron, F., Ciceri, F., Esteve, J., Gorin, N.C., Giebel, S., Mohty, M., Savani, B.N., et al. (2016). Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow TransPlant 51, 1431–1438.CrossRefGoogle Scholar
  11. Wang, Y., Chen, H., Chen, J., Han, M., Hu, J.D., Jiong Hu, J.D., Huang, H., Lai, Y., Liu, D., Liu, Q., et al. (2018). The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China. Cancer Lett 438, 63–75.CrossRefGoogle Scholar
  12. Wang, Y., Liu, D.H., Fan, Z.P., Sun, J., Wu, X.J., Ma, X., Xu, L.P., Liu, K. Y., Liu, Q.F., Wu, D.P., et al. (2012a). Prevention of relapse using DLI can increase survival following HLA-identical transplantation in patients with advanced-stage acute leukemia: a multi-center study. Clin Transplant 26, 635–643CrossRefGoogle Scholar
  13. Wang, Y., Liu, D.H., Xu, L.P., Liu, K.Y., Chen, H., Zhang, X.H., Chen, Y. H., Han, W., Wang, F.R., Wang, J.Z., et al. (2012b). Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis. Bone Marrow Transplant 47, 1099–1104.CrossRefGoogle Scholar
  14. Wang, Y., Wu, D.P., Liu, Q.F., Qin, Y.Z., Wang, J.B., Xu, L.P., Liu, Y.R., Zhu, H.H., Chen, J., Dai, M., et al. (2014). In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification. Blood 124, 1880–1886.CrossRefGoogle Scholar
  15. Yan, C.H., Liu, D.H., Liu, K.Y., Xu, L.P., Liu, Y.R., Chen, H., Han, W., Wang, Y., Qin, Y.Z., and Huang, X.J. (2012). Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 119, 3256–3262.CrossRefGoogle Scholar
  16. Yan, C.H., Liu, Q.F., Wu, D.P., Zhang, X., Xu, L.P., Zhang, X.H., Wang, Y., Huang, H., Bai, H., Huang, F., et al. (2017). Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease and graft-versus-host disease-guided multiple DLIs could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractory/relapsed acute leukemia. Biol Blood Marrow Transplant 23, 1311–1319.CrossRefGoogle Scholar
  17. Yan, C.H., Wang, J.Z., Liu, D.H., Xu, L.P., Chen, H., Liu, K.Y., and Huang, X.J. (2013). Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and a. Eur J Haematol 7.Google Scholar
  18. Yan, C.H., Wang, Y., Wang, J.Z., Chen, Y.H., Chen, Y., Wang, F.R., Sun, Y. Q., Mo, X.D., Han, W., Chen, H., et al. (2016). Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant. J Hematol Oncol 9, 87.CrossRefGoogle Scholar
  19. Yu, X., Xu, L., Chang, Y., Huang, X., and Zhao, X. (2018). Rapid reconstitution of NK1 cells after allogeneic transplantation is associated with a reduced incidence of graft-versus-host disease. Sci China Life Sci 61, 902–911.CrossRefGoogle Scholar
  20. Zhao, X.S., Liu, Y.R., Zhu, H.H., Xu, L.P., Liu, D.H., Liu, K.Y., and Huang, X.J. (2012). Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation. Ann Hematol 91, 183–192.CrossRefGoogle Scholar

Copyright information

© Science China Press and Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Yu Wang
    • 1
  • Lanping Xu
    • 1
  • Chenhua Yan
    • 1
  • Xiaojun Huang
    • 1
    • 2
    Email author
  1. 1.Peking University People’s HospitalPeking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell TransplantationBeijingChina
  2. 2.Peking-Tsinghua Center for Life SciencesBeijingChina

Personalised recommendations